Factors associated with cytoreducibility among women with ovarian carcinoma

Gynecologic Oncology

Volumn 95, Issue 2, 2004, Pages 377-383

  Eltabbakh, Gamal H ^a   Mount, Sharon L ^a   Beatty, Barbara ^a   Simmons Arnold, Linda ^a   Cooper, Kumarasen ^a   Morgan, Anne ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; GLUTATHIONE TRANSFERASE; GLYCOPROTEIN P; LUNG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL X; PROTEIN P21; PROTEIN P53;

ADULT; ADVANCED CANCER; AGED; APOPTOSIS; ASCITES; CANCER GRADING; CANCER STAGING; CANCER SURGERY; CLINICAL CHEMISTRY; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DISEASE ASSOCIATION; EPITHELIUM; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MOLECULAR MECHANICS; MULTIVARIATE ANALYSIS; OVARY CANCER; PERITONEUM CANCER; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; REGULATORY MECHANISM; REVIEW; SURGICAL TECHNIQUE;

EID: 7444262835     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.07.045     Document Type: Article

References (30)

1. C.T. Griffiths Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma Natl. Cancer Inst. Monogr. 42 1975 101 104
2. W.J. Hoskins, W.P. McGuire, M.F. Brady, H.D. Homesley, W.T. Creasman, and M. Berman The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma Am. J. Obstet. Gynecol. 170 1994 974 980
3. D.S. Chi, J.B. Liao, L.F. Leon, E.S. Venkatraman, M.L. Hensley, and D. Bhaskaran Identification of prognostic factors in advanced epithelial ovarian carcinoma Gynecol. Oncol. 82 2001 532 537
4. A.P. Makar, M. Baekelandt, C.G. Tropé, and G.B. Kristensen The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer Gynecol. Oncol. 56 1995 175 180
5. G.H. Eltabbakh, B.A. Werness, M.S. Piver, and L.E. Blumenson Prognostic factors in extra ovarian primary peritoneal carcinoma Gynecol. Oncol. 71 1998 230 239
6. S.M. Eisenkop, R.L. Friedman, and H.-J. Want Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study Gynecol. Oncol. 69 1998 103 108
7. A.L. Covens A critique of surgical cytoreduction in advanced ovarian cancer Gynecol. Oncol. 78 2000 269 374
8. R.W. Hunter, N. Alexander, and W.P. Soutter Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis? Am. J. Obstet. Gynecol. 166 1992 504 511
9. S.F. Serov, R.E. Scully, and L.H. Sobin Histologic typing of ovarian tumors (International histological classification of tumors. No. 9) 1973 World Health Organization Geneva 17 54
10. S.G. Silverberg Histopathologic grading of ovarian carcinoma: a review and proposal Int. J. Gynecol. Pathol. 19 2000 7 15
11. Cancer Committee of the International Federation of Gynecology and Obstetrics Staging announcement: FIGO Cancer Committee Gynecol. Oncol. 25 1986 383
12. J.D. Bloss, S.Y. Liao, R.E. Buller, A. Manneta, M.L. Berman, and S. McMeekin Extraovarian peritoneal serous papillary carcinoma: a case-control retrospective comparison to papillary adenocarcinoma of the ovary Gynecol. Oncol. 50 1993 347 351
13. J.P. Neijt, W.W. ten Bokkel Huinink, M.E.L. van der Burg, A.T. van Oosterom, P.H.B. Willemse, and J.B. Vermorken Long-term survival in ovarian cancer Eur. J. Cancer 27 1991 1367 1372
14. S.M. Eisenkop, and N.M. Spirtos Procedures required to accomplish complete cytoreduction of ovarian cancer: is there a correlation with "biological aggressiveness" and survival? Gynecol. Oncol. 82 2001 435 441
15. W.J. Hoskins, B.N. Bundy, J.T. Thigpen, and G.A. Omura The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study Gynecol. Oncol. 47 1992 159 166
16. M.E. Potter, E.E. Partridge, K.D. Hatch, S. Soong, J.M. Austin, and H.M. Shingleton Primary surgical therapy for ovarian cancer: how much and when Gynecol. Oncol. 40 1992 195 200
17. T. Le, G.V. Krepart, R.J. Lotocki, and M.S. Heywood Does debulking surgery improve survival in biologically aggressive ovarian carcinoma? Gynecol. Oncol. 67 1997 208 214
18. G.H. Eltabbakh, J.L. Belinson, A.W. Kennedy, C.V. Biscotti, G. Casey, and R.R. Tubbs p53 overexpression is not an independent prognostic factor for patients with primary ovarian epithelial cancer Cancer 80 1997 892 898
19. M.A. Levesque, D. Katsros, H. Yu, P. Zola, P. Sismondi, and G. Giatdina Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma Cancer 75 1995 1327 1338
20. P.I. Klemi, L. Pylkkanen, P. Kiiholma, K. Kurvinen, and H. Loensuu p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma Cancer 76 1996 1201 1208
21. L.A. Allan, M.K. Campbell, B.J. Milner, D.M. Eccles, R.C.F. Leonard, and D.E. Parkin The significance of p53 mutation and overexpression in ovarian cancer prognosis Int. J. Gynecol. Cancer 6 1996 483 490
22. G. Casey, M.E. Lopez, J.C. Ramos, S.J. Plummer, E.J. Arboleda, and M. Shaughnessy DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies Oncogene 13 1996 1971 1981
23. S. Sjorgen, M. Inganas, T. Norberg, A. Lindgren, H. Nordgren, and N. Holbert The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry J. Natl. Cancer Inst. 88 1996 173 182
24. S.C. Righetti, G.D. Torre, S. Pilotti, S. Menard, F. Ottone, and M.I. Colnaghi A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma Cancer Res. 56 1996 689 693
25. G. Ferrandina, A. Fagotti, M.G. Salerno, P.G. Natali, M. Mottolese, and F. Maneschi p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancer Br. J. Cancer 81 1999 733 740
26. F. Buttitta, A. Marchetti, A. Gadducci, S. Pellegrini, M. Morganti, and V. Carnicelli p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study Br. J. Cancer 75 2 1997 230 235
27. S. Sato, J. Kigawa, Y. Minagawa, M. Okada, M. Shimada, and M. Takahashi Chemosensitivity and p53-dependent apoptosis in epithelial ovarian carcinoma Cancer 86 1999 1307 1313
28. B.E. Nelson, A.T. Rosenfeld, and P.E. Schwartz Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma J. Clin. Oncol. 11 1993 166 172
29. J.P. Geisler, G.A. Miller, T.H. Lee, R.M. Harwood, M.C. Wiemann, and H.E. Geisler Relationship of preoperative serum CA-125 to survival in epithelial ovarian carcinoma J. Reprod. Med. 41 1996 14 22
30. D.S. Chi, E.S. Venkatraman, V. Masson, and W.J. Hoskins The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma Gynecol. Oncol. 77 2000 227 231